GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
L

LeonaBio LONA · USD

Health Care · US listing · 🇺🇸 United States

Compare

2.49

-6.04%

Close of 19 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

Price performance

Chart by TradingView, with its own licensed prices

LeonaBio — daily LONA Delayed
Market value
$23.3m
Last close × shares
Volume
83.7k
Shares, 19 Nov 2026

About LeonaBio

From its filings with the US Securities and Exchange Commission

SEC filings

LeonaBio is based in Bothell, Washington. Its shares trade on Nasdaq under the ticker LONA. The SEC classifies its business as biological products, (no diagnostic substances). In the fiscal year to 31 December 2025, it reported a net loss of $105.6m. At that date it held total assets of $92.2m and shareholders' equity of $27.8m.

In its own words

We are a clinical-stage biopharmaceutical company dedicated to the development of novel therapeutics for high unmet medical needs, including treatment-resistant metastatic breast cancer and amyotrophic lateral sclerosis (“ALS”), with the goal of improving patients’ lives.

Following a review of potential therapeutic and business opportunities, we acquired rights to a promising late-stage asset, lasofoxifene, for the potential treatment of ESR1-mutated (“mESR1”) metastatic breast cancer in December 2025. This late-stage program has generated promising clinical data and we believe it represents a unique and exciting opportunity to diversify our pipeline. We believe this program fits well with our later-stage clinical development experience, and complements our in-house asset, ATH-1105, a Phase-2 ready program for the potential treatment of ALS.

The drug development landscape in both oncology and neuroscience is evolving rapidly, driven by breakthroughs in genetics, disease biology, and molecular pathway research. We are leveraging this scientific momentum to advance a pipeline of innovative, late-stage assets both internally developed and strategically in-licensed with the goal of accelerating their path to market and maximizing their clinical and commercial impact.

Quoted from its 10-K, filed 31 Mar 2026. Read the filing on SEC.gov ↗

More about LeonaBio →

Latest on LeonaBio

Our reporting

Next results

25 Mar 2027

Due on 25 Mar 2027. Analysts expect earnings of -0.65 a share.

Other Health Care listings

Scenario calculator

Try your own numbers. This is arithmetic, not a forecast.

Interactive

Gain or loss

—

Return

—

Leaves out fees, taxes and financing.

Frequently asked questions

What is LeonaBio's ticker?

LeonaBio trades as LONA on its US listing, under ISIN US04746L2034.

What was LeonaBio's last closing price?

2.49 on 19 Nov 2026. The figure is in USD and is never converted.

Sources and methodology

Chart
TradingView
Close and company data
SEC filings and our data supplier
News
Our reporting

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.